While waiting for "the cure," many of us would settle for more effective drugs that have fewer side effects. Let's talk about this at 9 p.m. (EST) Thursday, Sept. 24, on Twitter.
|Dr. Laurence Baker|
Here are the basics on Twitter: https://media.twitter.com/the-basics. Before the chat, you may want to learn about drug development here: http://www.cancer.net/research-and-advocacy/introduction-cancer-research/drug-discovery-and-development.
Dr. Baker, a professor of internal medicine and pharmacology at the University of Michigan Medical School in Ann Arbor, brings a wealth of knowledge to the subject. He has served as director for clinical research and hematology/oncology at UM’s Comprehensive Cancer Center; chairman of the Southwest Oncology Group, the largest clinical trials organization in the United States; executive director of the Sarcoma Alliance for Research through Collaboration, a national cooperative group that runs sarcoma clinical trials; and president of the Connective Tissue Oncology Society, an international group of sarcoma physicians and scientists.
|Corrie Painter, PhD|
I'll update this post as more people commit to the chat.
This year has brought exciting news on trabectedin (Yondelis), eribulin (Halaven), aldoxorubicin and evofosfamide (TH-302). Some of you may be following the news on other experimental drugs, wondering why it takes so long for them to get FDA approval. Other possible questions include:
-- How long does it take and how much does it cost to develop new drugs?
-- Why does it take longer for some drugs to be approved in the U.S.? Yondelis, for example, is already approved in many countries.
-- What are the challenges of developing drugs for rare cancers like sarcoma?
-- Are there initiatives to speed up the process without sacrificing safety?
-- In addition to raising money for research, how can people help speed up the process?
What would you like to ask?